Management of bevacizumab toxicity for cancer therapy / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 711-714, 2011.
Artículo
en Chino
| WPRIM
| ID: wpr-422115
ABSTRACT
Bevacizumab is an efficient and low-toxicity monoclonal antibody towards serum ventricular endothelial growth factor.At present,bevacizumab has been approved by FDA to use clinically for kinds of cancer,such as colorectal cancer,lung cancer,kidney cancer and breast cancer.As more and more patients received bevacizumab cliniclly,it's toxicities are also focused on increasingly.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of International Oncology
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS